Table III.
Variables | HR | 95% CI | P-value |
---|---|---|---|
Recurrence-free survival | |||
Age (>70/≤70 years) | 1.908 | 0.686–5.302 | 0.215 |
Gender (male/female) | 2.333 | 0.680–8.009 | 0.178 |
ECOG PS (≥1/0) | 0.873 | 0.355–2.149 | 0.768 |
Tumor size (>10/≤10 cm) | 3.405 | 0.990–11.714 | 0.052 |
Pathologic T stage (T2–3/T1) | 2.430 | 0.875–6.750 | 0.088 |
Fuhrman nuclear grade (G3–4/G1–2) | 3.433 | 1.350–8.727 | 0.010 |
CD44 expression (high/low) | 9.669 | 3.869–24.162 | <0.001 |
Disease-specific survival | |||
Age (>70/≤70 years) | 3.571 | 1.165–10.947 | 0.026 |
Gender (male/female) | 4.928 | 0.641–37.908 | 0.125 |
ECOG PS (≥1/0) | 0.911 | 0.306–2.710 | 0.867 |
Tumor size (>10/≤10 cm) | 2.995 | 0.663–13.520 | 0.154 |
Pathologic T stage (T2–3/T1) | 2.855 | 0.785–10.377 | 0.111 |
Fuhrman nuclear grade (G3–4/G1–2) | 4.683 | 1.572–13.954 | 0.006 |
CD44 expression (high/low) | 10.421 | 3.393–32.002 | <0.001 |
Overall survival | |||
Age (>70/≤70 years) | 2.925 | 1.178–7.265 | 0.021 |
Gender (male/female) | 1.328 | 0.487–3.627 | 0.579 |
ECOG PS (≥1/0) | 0.855 | 0.363–2.012 | 0.719 |
Tumor size (>10/≤10 cm) | 1.754 | 0.408–7.535 | 0.450 |
Pathologic T stage (T2–3/T1) | 1.720 | 0.694–4.262 | 0.242 |
Fuhrman nuclear grade (G3–4/G1–2) | 2.767 | 1.115–6.863 | 0.028 |
CD44 expression (high/low) | 5.509 | 2.274–13.348 | <0.001 |
HR, hazard ratio; CI, confidence interval. ECOG, Eastern Cooperative Oncology Group; PS, performance status.